- Open
- 195.00
- High
- 196.50
- Low
- 190.54
- Close
- 195.00
- Change
- -8.00 (-4.00%)
- Volume
- 7,016
| 3 Sept 2026 | 07:00:05 | HUTCHMED Licenses KRAS-EGFR-Antibody to GSK |
| 1 Sept 2026 | 07:00:12 | SANOVO trial demonstrated significant PFS benefit |
| 28 Aug 2026 | 07:00:04 | NMPA Approval for ATLED® (Fanregratinib) for ICC |
| 18 Aug 2026 | 10:00:01 | Announcement pursuant to AIM Rule 17 Schedule 2(g) |
| 17 Aug 2026 | 07:00:07 | Orpathys+Tagrisso improved PFS & OS in EGFRm lung |
Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.
| 3 Sept 2026 | 07:00:05 | HUTCHMED Licenses KRAS-EGFR-Antibody to GSK |
| 1 Sept 2026 | 07:00:12 | SANOVO trial demonstrated significant PFS benefit |
| 28 Aug 2026 | 07:00:04 | NMPA Approval for ATLED® (Fanregratinib) for ICC |
| 18 Aug 2026 | 10:00:01 | Announcement pursuant to AIM Rule 17 Schedule 2(g) |
| 17 Aug 2026 | 07:00:07 | Orpathys+Tagrisso improved PFS & OS in EGFRm lung |
Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.
| Issuer | Mkt cap | 1Y |
|---|---|---|
HCMHutchmed (China) Limited | £1.70bn | -0.1% |
| £317m | -0.4% | |
| £273m | -0.1% | |
| £59m | +0.8% | |
| £37m | — | |
| £16m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
HCMHutchmed (China) Limited | £1.70bn | -0.1% |
| £317m | -0.4% | |
| £273m | -0.1% | |
| £59m | +0.8% | |
| £37m | — | |
| £16m | -0.4% |